Rapid Fire-Top Articles You Need to Know

Similar documents
Updates in Diagnosis & Management of VTE

Updates in Diagnosis & Management of VTE

DEEP VEIN THROMBOSIS (DVT): TREATMENT

With All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis

Mabel Labrada, MD Miami VA Medical Center

Deep Vein Thrombosis and Pulmonary Embolus: Updates From ACCP, AC Forum & ESC

Keynote lecture: Oral anticoagulation and DVT

Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR

Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty: The EPCAT II Trial

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism

Managing Perioperative Anticoagulation. Edie Shen MD

Perioperative Management of the Anticoagulated Patient

Obesity, renal failure, HIT: which anticoagulant to use?

Duration of anticoagulation

10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC

Acute and long-term treatment of PE. Cecilia Becattini University of Perugia

USE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY

DVT - initial management NSCCG

Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium

Clinical Guideline for Anticoagulation in VTE

Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018

Venous Thromboembolism (VTE) in Myeloma. Christine Chen May 2017

Anticoagulation Forum: Management of Tiny Clots

Challenges in Anticoagulation and Thromboembolism

Venous Thromboembolic Disease Update

Aspirin as Venous Thromboprophylaxis

Disclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None

DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)

Challenges in Anticoagulation Bridging and Emerging Therapies. Disclosures and Relationships. Objectives. Dr. Cumbler has no conflicts of interest

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute

The clinical relevance of AMPLIFY programme

Trombosi venose superficiali e trombosi venose distali

Dr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital Foundation Trust

Direct oral anticoagulants to prevent VTE recurrence: full or reduced dosage? MA Sevestre CHU Amiens

The latest on the diagnosis and treatment of venous thromboembolism

Updates in venous thromboembolism. Cecilia Becattini University of Perugia

Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT

Anticoagulation Update: VTE Guidelines update, DOACs, procedural warfarin interruption, and icentra (whew!)

UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS

Implications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis: a case based approach

Managing Anticoagulation in the Hospitalized Patient

The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for

A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations

New Oral Anticoagulant Drugs in the Prevention of DVT

What s new with DOACs? Defining place in therapy for edoxaban &

DOACs in SPECIAL POPULATIONS

A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism

Medical Patients: A Population at Risk

Suspected Deep Vein Thrombosis (DVT) Pathway for Non Pregnant patients Updated November 2016, with new D-dimer reference range

Treatment Options and How They Work

Clinical Cases with Deep Venous Thrombosis - The position of Apixaban Stavros KAKKOS, MD, MSc, PhD, RVT

Updates in Management of Venous Thromboembolic Disease

Direct Oral Anticoagulant Use in Older Adults Brian Skinner, PharmD

Top 5 (or so) Hematology Consults. Tom DeLoughery, MD FACP FAWM. Oregon Health and Sciences University DISCLOSURE

VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT

Expanding the treatment options of Superficial vein thrombosis with Rivaroxaban

2.5 Other Hematology Consult:

Objectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?

New Oral Anticoagulants

Changing the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum

DOACs in CAT. Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD

Current issues in the management of Superficial Vein Thrombosis - SVT

Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren

Misunderstandings of Venous thromboembolism prophylaxis

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015

Duration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016

Updates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017

Anticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita

Duration of Therapy for Venous Thromboembolism

Venous Thromboembolism Prophylaxis

Do s and Don t of DOACs DISCLOSURE

CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow

VTE: New Evidence, Best Practices, and Controversies

Results from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY

Warfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin

Thrombosis. Tom DeLoughery, MD FACP. Oregon Health and Sciences University

Perioperative Management of Anticoagulation

Primary VTE Thromboprophylaxis

2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17

A VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention

10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI

Perioperative VTE Prophylaxis

Acute Care: Understanding Direct Oral Anticoagulants (DOACs)

Venous Thromboembolism Management: Bridging the Gap Between Inpatient and Outpatient. Disclosure. Technician Objectives. Pharmacist Objectives

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC

Vascular Protection: Preventing Thrombotic Complications of VTE and PAD

New Guidance in AT10 Clive Kearon, MD, PhD,

Oral Anticoagulation Drug Class Prior Authorization Protocol

Blood Day for Primary Care

Superficial Thrombophlebitis Treatment Guideline Review

Edoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor

New Anticoagulants Therapies

Venous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital

Prostate Biopsy Alerts

Anticoagulation Update: DOACs, VTE Guidelines, Bridging and icentra

CHAPTER 2 VENOUS THROMBOEMBOLISM

Hemostasis and Thrombosis for Primary Care Providers: An Update. Andrew D. Leavitt, MD. May 21, Topic Outline. Direct Oral Anti-Coagulants DOACs

EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS

Acute and long-term treatment of VTE. Cecilia Becattini University of Perugia

Transcription:

Rapid Fire-Top Articles You Need to Know TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE- SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

Financial Disclosures-NONE

THESE SHOULD BE AT YOUR FINGERTIPS Kearon et al. Chest. 2016;149(2):315-352. Dohert yju et al. JACC 2017

Volume 41, Issue 1, January 2016 Special Issue: Management of Venous Thromboembolism: Clinical Guidance from the Anticoagulation Forum

Secondary Prevention of VTE A 57 year old man with DVT 6 months ago possibly mildly provoked (weeks after 4 hour plane flight) is on rivaroxaban 20 mg daily. For ongoing VTE prevention you recommend: 1) Continue rivaroxaban 20 mg po daily 2) Transition to rivaroxaban 10 mg po daily 3) Switch to apixaban 2.5 mg twice daily 4) Stop rivaroxaban 5) Stop rivaroxaban. Start ASA 81 mg po daily 6) Did you say happy hour?

Duration of Anticoagulation for VTE: 2016 CHEST and AC Forum Guidelines/Guidance Indication CHEST 2016 1 AC Forum 2016 2 1st provoked VTE 3 mo 3 mo (surgical) a 3 mo (medical) 1st unprovoked VTE Extended b Extended 2nd unprovoked VTE Extended b Extended VTE + cancer Extended b Extended a Unless risk factors for recurrence persist b No scheduled stop date, unless high bleeding risk. 1. Kearon C et al. Chest. 2016;149(2):315-352. 2. Streiff MB et al. J Thromb Thrombolysis. 2016;41:32-67. 7

Options for Secondary Prevention of VTE Agent Risk Reduction Regimen None 0% Full-dose anticoagulation 1-3 ~80-90% Warfarin INR 2 3; maintenance dosing dabigatran, rivaroxaban, apixaban, edoxaban Low dose DOAC₂ ~80% Apixaban 2.5 mg BID Low-intensity warfarin 3 75% Warfarin INR 1.5 1.9 ASA 4 32% 100 mg po daily CHEST 2016: In patients with an unprovoked proximal VTE who are stopping anticoagulant therapy and do not have a contraindication to ASA we suggest ASA..to prevent recurrent VTE 1. Agnelli G et al. N Engl J Med. 2013;368:699-708. 2. EINSTEIN INVESTIGATORS N Engl J Med 363;26 3. Kearon C et al. N Engl J Med. 2003;349:631-639. 4. Brighton TA et al. N Engl J Med. 2012;367:1979-1987. 8

8.8% 1.7% Agnelli etal NEJM 2013

After 6-12 months of anticoagulation for VTE Provoked (~60%) or unprovoked (~40%) Clinical equipose about indefinite AC therapy One year follow up Weitz et al. N Engl J Med March 2017

Weitz et al. N Engl J Med March 2017 Rivaroxaban 20 mg Rivaroxaban 10 mg All Provoked VTE Recurrent VTE BLEED 1.5% 1.4% 1.5% 3.3% 1.2% 0.9% 1.0% 2.4% ASA 81 mg 4.4% 3.6% 8.8% 2.0%

Secondary Prevention of VTE A 57 year old man with Extending DVT 6 treatment months ago beyond possibly 3 months could be considered mildly provoked (weeks after 4 hour plane flight) is on with provoked VTE.The rivaroxaban 20 mg daily. results For of this ongoing trail cannot VTE prevention be you recommend: extended to patients who have 1) Continue rivaroxaban an unequivocal 20 mg poindication daily for long-term anticoagulation 2) Transition to rivaroxaban 10 therapy mg po daily 3) Switch to apixaban 2.5 mg twice daily 4) Stop rivaroxaban 5) Stop rivaroxaban. Start ASA 81 mg po daily 6) Did you say happy hour?

What To Do After the Bleed 76 y/o man with CAD (NSTEMI 2006), AFIB CHADS- Vasc=4 on warfarin and ASA is admitted with UGIB. INR is 3.0. He requires 3u PRBCs, vit K and FFP. EGD shows peptic ulcer disease. He is started on high dose PPI therapy, bx for H Pylori done. When should his anticoagulation be restarted? a) Never b) In two weeks c) In three months d) Let the primary provider deal with this one

What To Do After the Bleed Witt Hematology 2016

What To Do After the Bleed 76 y/o man with CAD (NSTEMI 2006), AFIB CHADS- Vasc=4 on warfarin and ASA is admitted with UGIB. INR is 3.0. He requires 3u PRBCs, vit K and FFP. EGD shows peptic ulcer disease. He is started Two weeks on high may dose provide PPI the best balance among GI therapy, bx for H Pylori done. bleed When recurrence should his, anticoagulation be restarted? thromboembolism and a) Never mortality b) In two weeks c) In three months d) Let the primary provider deal with this one

DOACs in Extremes of Weight A 56 year old obese man, BMI 42, weight 155 kg presents with bilateral lower extremity swelling. D-Dimer is elevated prompting bilateral lower extremity ultrasound. Ultrasound shows a DVT in LEFT common femoral, superficial femoral and popliteal vein. He is deemed appropriate for outpatient management of this VTE. What anticoagulant regimen do you recommend? 1. Rivaroxaban 15 mg BID x21 days then 20 mg daily 2. Apixaban 10 mg BID x 7 days then 5 mg BID 3. Enoxaparin bridging to warfarin 4. Admission for IV heparin bridging to warfarin 5. Do you have Ann Wittkowsky s cell phone number?

DOACs in Extremes of Weight Systematic review of 6 trials of DOACS vs warfarin n VTE Proportion of patient s classified as high body weight 15-28% Variability may be related to definition (ie > 90kg vs 100kg) Very little information on extreme body weight (eg < 40 kg, > 150 kg Di Minno MN et al. Ann Med. 2015 Feb;47(1):61-8

DOACS AND EXTREMES OF WEIGHT HIGH BODY WEIGHT NORMAL BODY WEIGHT LOW BODY WEIGHT Minno et al Ann Intern Med 2015 Feb;47(1):61-8

DOACs in Obesity Reduced exposure, lower peaks, shorter t 1/2 Martin et al Journal of Thrombosis and Haemostasis, 2016 14: 1308 1313

DOACs in Extremes of Weight ISTH RECOMMENDATIONS: Recommend standard dosing if BMI< 40 and weight < 120 kg. Suggest DOACS not be used if BMI> 40 or weight > 120 kg If DOACs used in BMI > 40 or weight> 120 kg suggest drug specific peak and trough level If level within expected range continue DOAC; if below suggest warfarin Martin et al. J Thromb Heamost 2016

DOACs in Extremes of Weight A 56 year old obese man, BMI 42, weight 155 kg presents with bilateral lower extremity swelling. D-Dimer is elevated prompting bilateral lower extremity ultrasound. Ultrasound shows a DVT in LEFT common femoral, superficial femoral and popliteal vein. He is deemed appropriate for outpatient management of this VTE. What anticoagulant regimen do you recommend? 1. Rivaroxaban 15 mg BID x21 days then 20 mg daily 2. Apixaban 10 mg BID x 7 days then 5 mg BID 3. Enoxaparin bridging to warfarin 4. Admission for IV heparin bridging to warfarin 5. Do you have Ann Wittkowsky s cell phone number?

Calf Vein DVT A 37 year old man presents with right calf pain one week after being kicked in calf during a soccer game. On exam right calf is 2 cm> left. U/S shows thrombosis in the peroneal vein. What anticoagulation regimen do you recommend? 1. Rivaroxaban 15 mg BID x 21 days then 20 mg daily to complete 3 months of therapy 2. Prophylactic dosing of LMWH or DOAC 3. No anticoagulation, return in one week for repeat ultrasound of lower extremity. 4. Um, is that a deep vein? The guy sitting next to me wants to know.

Also includes gastroc and soleus veins

Calf Vein DVT-CHEST 2016 Risk factors for extension: d-dimer +, extensive thrombosis close to proximal veins; active cancer, prior VTE, inpatient Kearon et al. Chest. 2016;149(2):315-352.

Calf Vein DVT-CHEST 2016 AC Forum clinical guidance We suggest treatment of distal DVT with anticoagulation versus observation. We suggest a duration of therapy 3 months. Streiff MB et al. J Thromb Thrombolysis. 2016;41:32-67..

Calf Vein DVT 1 st DVT, no cancer, outpatient only 6 weeks LMWH and GCS vs placebo and GCS U/S at 3-7 days and 42 days Outcome progression to proximal DVT or PE No difference in VTE, increased risk of bleeding Righini et al. Lancet Haematol 2016;3: e556 62

Calf Vein DVT A 37 year old man presents with right calf pain on week after being kicked in calf during a soccer game. On exam right calf is 2 cm> left. U/S shows thrombosis in the peroneal vein. What anticoagulation regimen do you recommend? 1. Rivaroxaban 15 mg BID x 21 days then 20 mg daily to complete 3 months of therapy 2. Prophylactic dosing of LMWH or DOAC 3. No anticoagulation, return in one week for repeat ultrasound of lower extremity. 4. Um, is that a deep vein? The guy sitting next to me wants to know.

Superficial Vein Thrombosis A 55 year old woman presents with painful palpable swelling over anterior left thigh. On exam she has a palpable cord concerning for SVT. She has an U/S which shows thrombosis of the greater saphenous vein extending from the calf proximally and terminating 6 cm from the deep femoral vein. What anticoagulant regimen do you recommend? a. Prophylactic fondaparinux b. Prophylactic rivaroxaban c. Full dose DOAC or warfarin d. NSAIDS and ice

Superficial Vein Thrombosis CHEST Guidelines Factors that favor the use of AC : extensive SVT; above the knee, close to saphenofemoral junction; severe symptoms; involvement of the greater saphenous vein; history of VTE or SVT; active cancer; recent surgery In patients with superficial vein thrombosis of the lower limb of at least 5 cm in length, we suggest the use of a prophylactic dose of fondaparinux or LMWH for 45 days over no anticoagulation (Grade 2B). Kearon C et al. Chest. 2012

Superficial Vein Thrombosis >400 pts symptomatic SVT riva 10 mg v fonda 2.5mg Symptomatic above the knee SVT of at least 5 cm length + other risk factor (>65, male,hx VTE, cancer, autoimmune disease, non-varicose veins) No difference in primary efficacy outcome After 6 weeks 7% recurrence risk in high risk patients (v 1.2% in CALISTO)

Superficial Vein Thrombosis A 55 year old woman presents with painful palpable swelling over anterior left thigh. On exam she has a palpable cord concerning for SVT. She has an u/s which shows thrombosis of the greater saphenous vein extending from the calf proximally and terminating 2 cm from the deep femoral vein. What anticoagulant regimen do you recommend? a. Prophylactic fondaparinux b. Prophylactic rivaroxaban c. Full dose DOAC or warfarin d. NSAIDS and ice

Reducing the Hospital Burden of HIT Not uncommon HIT occurs in 5% of those exposed to UFH Risk reduced 10 fold with LMWH High morbidity and mortality Thromboembolic complications 20-50% Expensive

Reducing the Hospital Burden of HIT McGowan KE, et al. Blood. 2016 Apr 21;127(16):1954-9

Avoid Heparin Protocol Systematic replacement of most IV and SQ UFH with SQ LMWH in prophylactic or therapeutic doses (remaining uses of UFH were for hemodialysis, intraoperative use for cardiovascular surgery, ACS) Replacement of heparinized saline in arterial and central venous lines with saline flushes Modification of order sets to exclude UFH options Removal of UFH stores from most nursing units. McGowan KE, et al. Blood. 2016 Apr 21;127(16):1954-9

Avoid Heparin Protocol ~40% reduction in suspected HIT ~80% reduction in HIT ~80% reduction in HIT related costs McGowan KE, et al. Blood. 2016 Apr 21;127(16):1954-9

Periprocedural Management of DOACs A 62 year old man with DM, CAD and aflutter is on dabigatran for stroke prevention. He is to undergo ablation procedure next month. He asks if he will need to stop his dabigatran prior to his procedure. What do you tell him? 1) Yes-hold 2 doses prior to the procedure 2) No-you don t have to stop it, just cross your fingers that it all goes ok.

Raval et al. Circulation. 2017;135:00 00

Calkins et al. N Engl J Med. 2017 Mar 19

Uninterrupted Dabigatran v. Warfarin Ablation 77% reduction in risk of major bleeding Calkins et al. N Engl J Med. 2017 Mar 19

Periprocedural Management of DOACs A 62 year old man with DM, CAD and aflutter is on dabigatran for stroke prevention. He is to undergo ablation procedure next month. He asks if he will need to stop his dabigatran prior to his procedure. What do you tell him? 1) Yes-hold 2 doses prior to the procedure 2) No-you don t have to stop it, just cross your fingers that it all goes ok.

Take Home Points Low dose rivaroxaban is an option for secondary prevention of VTE If decision is made to restart anticoagulation after GIB in patients on warfarin for AFIB, reinitiate warfarin on day 7-14 Consider withholding anticoagulation and opting for follow up U/S in low risk calf vein thrombosis 6 weeks of low dose rivaroxaban is an option for treatment of SVT-consider longer duration if high risk Uninterrupted dabigatran appears safe in patients undergoing ablation

THE END